

Lepu Medical Technology (Beijing) Co., Ltd.

2023 First Quarter Report

The Company and all members of the Board of Directors warrant that the information disclosed is authentic, accurate and complete, and contains no false records, misleading statements or material omissions.

Hint of important contents:

1. The Board of Directors, the Board of Supervisors, directors, supervisors, and senior executives of the Company shall guarantee the truthfulness, accuracy and completeness of the content of the quarterly report, without any false records, misleading statements or major omissions, and also assume several and joint legal liabilities.

2. The head of the Company, chief financial officer and person in charge of accounting department hereby confirm that the financial statement enclosed in this quarterly report is true, accurate and complete.

3. Whether the First Quarter Report has been audited

Yes No

I. Major Financial Data

(I) Major Accounting Data and Financial Indicators

Does the Company need to retrospectively adjust or restate previous annual accounting data

Yes No

	Three Months Ended March 31, 2023	Three Months Ended March 31, 2022	% Change
Operating revenue(RMB)	2,437,202,386.92	2,549,111,243.52	-4.39%
Net profit attributable to shareholders of the Company (RMB)	596,924,222.49	545,393,656.31	9.45%
Net profit attributable to shareholders of the Company after deducting non-recurring profit and loss (RMB)	562,429,846.30	547,208,342.77	2.78%
Net cash flows from operating activities (RMB)	-134,203,435.01	448,932,891.19	-129.89%
Basic earnings per share (RMB /share)	0.3205	0.3054	4.94%
Diluted earnings per share (RMB /share)	0.3177	0.3030	4.85%
Return on weighted average	3.86%	4.68%	-0.82%

net assets	Three Months Ended March 31, 2023	Year Ended December 31, 2022	% Change
Total assets (RMB)	24,559,902,516.86	24,484,033,145.01	0.31%
Total equity attributable to shareholders of the Company(RMB)	15,823,636,468.24	15,146,202,761.30	4.47%

From the end of the reporting period to the disclosure date of the quarterly report, whether the share capital of the Company has changed due to the issuance of new shares, additional issuance, allotment, equity incentive exercise, repurchase and other reasons and whether the share capital of the Company has affected the amount of owners' equity.

Yes No

	This reporting period
Preferred share dividends paid (RMB)	0.00
Interest paid on perpetual bonds (RMB)	0.00

(II) Items and amounts of non-recurring profits or losses

Applicable Not applicable

Unit: RMB

Item	Amount in this reporting period	Instructions
Profits and losses on disposal of non-current assets (including the write-off of provision for asset impairment)	1,253,000.35	
Government subsidies included in the current profits and losses (except those that are closely related to the Company's normal business operations, comply with national policies and regulations and are continuously available according to certain standard quota or quantity)	43,400,787.53	
Except effective hedging business related to the Company's normal business operations, profits and losses from fair value changes caused by financial assets and liabilities held-for-trading, and investment income acquired from disposal of financial assets and liabilities held-for-trading and available-for-sale financial assets	4,039,260.35	
Non-operating revenues and expenses other than those mentioned above	-1,222,905.12	
Other items of profits and losses conforming to the definition of non-recurring profits and losses	-1,092,850.26	
Less: Income tax expense	7,700,376.96	
Influenced amount of non-controlling interests (after-tax)	4,182,539.70	
Total	34,494,376.19	

Details of other profit and loss items complying with the definition of non-recurring profits or losses

Applicable Not Applicable

There are no details of other profit and loss items complying with the definition of non-recurring profits or losses.

Explanations for defining non-recurring profits and losses items listed in the *Explanatory Announcement No.1 on Disclosure of the Information of Companies Offering Their Securities to the Public - Non-recurring Profits and Losses* as recurring profits and losses

Applicable Not Applicable

There are no situations for defining non-recurring profits and losses items listed in the *Explanatory Announcement No.1 on Disclosure of the Information of Companies Offering Their Securities to the Public - Non-recurring Profits and Losses* as recurring profits and losses.

(III) Details and reasons of changes of major accounting data and financial indicators

Applicable Not applicable

1. During the reporting period, the Company's operating income was RMB 2437.2024 million, RMB 111.9089 million lower than that of the same period of last year, with a decrease of 4.39%, mainly due to the high cardinal utility of detection reagent products related to COVID-19 in the same period of last year.

1) After the volume-based procurement of coronary metal stents, the routine business of the Company's medical device plate quickly recovered to a good growth trend. In January, selective operation was basically stagnant nationwide due to COVID-19; In February and March, the sales volume was relatively normal; Under this circumstance, the portfolio of cardiovascular intervention innovative products still achieved year-on-year growth throughout the reporting period.

2) The pharmaceutical sector contributes long-term stable cash flow to the Company. During the reporting period, the income of the pharmaceutical sector was basically flat.

3) The medical care solution sector is a new business sectors actively cultivated by the Company. This business is innovative for the Company, and it is a constantly increasing investment to realize the advantages of health management channels for end users by relying on data technology. The operating income of the Company's medical care solution sector had a year-on-year of 16.06% .

During the reporting period, the Company achieved a net profit of RMB 618.3185 million, with an increase of 10.00% compared with the same period of the last year; Net profits attributable to shareholders of the Company was RMB 596.9242 million, with a increase of 9.45% compared with that in the last year; net profit attributable to shareholders of the Company after deducting non-recurring profit and loss was RMB 562.4298 million, with an increase of 2.78% compared with that of the last year; After the influences of share-based payment fee confirmed by Lepu Diagnostic Technology and Lepu Xintai Technology and the restricted stock plan issued at the end of the period of the Company are eliminated of RMB 60.6962 million and exchange loss of RMB 43.5413 million, the net profit attributable to shareholders of the Company after non-recurring gains and losses were deducted was RMB 652.8196, with a year-on-year increase of 15.61%.

During the reporting period, non-recurring profit attributed to shareholders of the Company were RMB 34.4944 million, there was a non-recurring business loss of RMB 1.8147 million in

the same period of the last year, and the year-on-year gains increased significantly, mainly due to the increase in government subsidies received by the Company during the reporting period.

3. During the reporting period, the financial expenses were RMB 54.4281 million, with an increase of RMB 25.1756 million compared with that in the same period of last year, with an increasing amplitude of 86.06%, mainly due to the large fluctuation of foreign currency exchange rate during the reporting period, resulting in the exchange loss of RMB 43.5413 million due to the time impact of the Company's settlement of foreign exchange in accordance with the foreign exchange management approval process, the income from exchange in the same period of the last year was RMB 4.3036 million.

4. Other incomes during the reporting period was RMB 25.7539 million, with an increase of RMB 17.0794 million in the same period of last year, with a growth rate of 196.89%, mainly due to the increase in government subsidies related to daily activities received by the Company during the reporting period.

5. During the reporting period, the gains from changes in fair value was RMB 5.7596 million, an increase of RMB 10.7396 million compared with the loss from changes in fair value of RMB 4.9800 million in the same period of last year, with an increasing amplitude of 215.65%, mainly due to the fluctuation of the market price of the shares held by the Company during the reporting period.

6. Other non-operating incomes during the reporting period was RMB 33.1623 million, with an increase of RMB 29.9471 million in the same period of last year, with an increasing amplitude of 931.41%, mainly due to the increase in government subsidies related to daily activities received by the Company during the reporting period.

7. During the reporting period, the net outflow of cash flow from operating activities of the Company was RMB 134.2034 million, with a decrease of RMB 583.1363 million and with a decline amplitude of 129.89% compared with the net inflow of RMB 448.9329 million in the same period of the last year. The main influencing factors include: 1) In the fourth quarter of 2022, the advance payment received by the Company due to emergency products was greatly refunded due to the weakened customer demand; 2) There is a delay in the settlement of some sales funds of e-commerce platforms; 3) The labor costs required for emergency product production at the end of the last year and the funds for purchasing raw materials and materials is paid in this quarter; 4) The payment of value-added tax, income tax and other taxes and fees in accordance with relevant national tax management policies increased substantially year-on-year.

8. During the reporting period, the net outflow of cash flow from the investing activities of the Company was RMB 212.4100 million, with a decrease of RMB 224.3208 million compared with the net outflow of RMB 436.7307 million in the same period of last year, and the increasing

amplitude to the contribution to cash flow was 51.36%, mainly due to the Company's recovery of wealth management products during the reporting period.

9. During the reporting period, the net inflow of cash flow generated by the Company's financing activities was RMB 250.4781 million, with an increase of RMB 415.8518 million compared with the net outflow of RMB 165.3737 million in the same period of the last year, with an increasing amplitude of 251.46%, mainly due to the Company's increase in loans during the reporting period to prepare for the medium-term notes due in April; During the same period of last year, RMB 40.0200 million was paid to repurchase of treasury shares and a financing margin of RMB 67.0098 million was increased. There was no such expenditure in this reporting period.

10. At the end of the reporting period, the contractual liabilities of the Company were RMB 320.0777 million, with a decrease of RMB 411.0382 million and with a decline rate of 56.22% compared with those at the beginning of the year, mainly due to the fact that a large number of advances received of sales at the end of last year have been delivered or refunded in this period.

11. At the end of the reporting period, the Company's salary payable to employees was RMB 61.7871 million, with a decrease of RMB 144.9143 million or a decline rate of 70.11% compared with those at the beginning of the year, mainly due to the Company's payment of the bonus accrued in the previous year during the reporting period.

12. At the end of the reporting period, the Company's long-term loan was RMB 1167.7913 million, with an increase of RMB 436.2429 million or a increasing amplitude of 59.63% compared with those at the beginning of the year, mainly due to the Company's increase in loans during the reporting period to prepare for the medium-term notes due in April.

13. At the end of the reporting period, other comprehensive loss of the Company was RMB 48.9949 million, with an income increase of RMB 41.7693 million or an increasing amplitude of 46.02% compared with the loss of RMB 90.7642 million at the beginning of the year, mainly due to the increase in the fair value of other equity instruments investment during the reporting period.

II. Information of Shareholders

(I) Table of total number of common stockholders and preferred shareholders recovering voting rights and shareholdings of top ten shareholders

Unit: Share

Total number of common shareholders at the end of the reporting period	83,934	The sum of preferred stock shareholders recovering voting rights at the end of reporting period (if any)	0		
Shareholding of the top 10 shareholders					
Shareholders' name	Nature of shareholder	Shareholding ratio (%)	Number of shares held	Pledge, marking or freezing	
				Number of shares held with restricted conditions	Quantity
				Stock status	

725th Research Institute of China State Shipbuilding Corporation Limited	State-owned legal person	12.98%	244,063,788.00			
PU Zhongjie	Domestic natural person	12.13%	228,074,749.00	171,056,062.00	Pledge	167,230,000.00
WP MEDICAL TECHNOLOGIES, INC	Foreign legal person	6.59%	123,968,600.00	92,976,450.00		
Hong Kong Securities Clearing Company Limited	Foreign legal person	5.54%	104,140,845.00			
Houde Yimin (Beijing) Investment Management Co., Ltd.	Domestic non-state-owned legal person	3.60%	67,750,000.00		Pledge	23,634,454.00
Houde Yimin (Ningbo) Investment Management Co., Ltd.	Domestic non-state-owned legal person	1.91%	35,850,000.00			
Bank Of China Limited - Huabao CSI medical trading open-end index securities investment fund	Others	1.29%	24,287,335.00			
China Construction Bank Corporation - mixed securities investment fund for China-Europe pension industry	Others	0.90%	16,939,705.00			
Monetary Authority of Macao - self-owned funds	Foreign legal person	0.84%	15,704,655.00			
XIONG Qingchuan	Domestic natural person	0.67%	12,623,900.00			
Shareholding of the top 10 shareholders with non-restricted conditions						
Shareholders' name	Number of shares held without restricted conditions	Type of share				
		Type of share	Quantity			
725th Research Institute of China State Shipbuilding Corporation Limited	244,063,788.00	RMB common share	244,063,788.00			
Hong Kong Securities Clearing Company Limited	104,140,845.00	RMB common share	104,140,845.00			
Houde Yimin (Beijing) Investment	67,750,000.00	RMB common	67,750,000.00			

Management Co., Ltd.		share	
PU Zhongjie	57,018,687.00	RMB common share	57,018,687.00
Houde Yimin (Ningbo) Investment Management Co., Ltd.	35,850,000.00	RMB common share	35,850,000.00
WP MEDICAL TECHNOLOGIES, INC	30,992,150.00	RMB common share	30,992,150.00
Bank Of China Limited - Huabao CSI medical trading open-end index securities investment fund	24,287,335.00	RMB common share	24,287,335.00
China Construction Bank Corporation - mixed securities investment fund for China-Europe pension industry	16,939,705.00	RMB common share	16,939,705.00
Monetary Authority of Macao - self-owned funds	15,704,655.00	RMB common share	15,704,655.00
XIONG Qingchuan	12,623,900.00	RMB common share	12,623,900.00
Description of associated relationships or concerted action of the above shareholders	Mr. PU Zhongjie, WP Medical Technologies, Inc., Houde Yimin (Beijing) Investment Management Co., Ltd. and Houde Yimin (Ningbo) Investment Management Co., Ltd. were persons acting in concert within the meaning of PRC law. There is no relationship between other shareholders of the Company or concerted action as stipulated in <i>Measures for the Administration of Acquisition of Listed Companies</i> (Order No.35 of China Securities Regulatory Commission).		

(II) Table of total number of the preferred shareholders and shareholdings of top 10 preferred shareholders of the Company

Applicable Not Applicable

(III) Statement of restricted share change

Applicable Not applicable

Unit: Share

Shareholders' name	Quantity of restricted stocks at the beginning of the period	Quantity of stocks removed with restrictions on sales in current period	Quantity of stocks added with restrictions on sales in current period	Quantity of restricted stocks at the end of the period	Reason for restriction on sales	Date of cancellation of the restriction
PU Zhongjie	173,402,757.00	2,346,695.00		171,056,062.00	Restricted circulation stock held by senior executives	During Mr. PU Zhongjie's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the

						Company within half a year after his resignation.
WP MEDICAL TECHNOLOGIES, INC	92,976,450.00			92,976,450.00	Pre-sale restricted shares	During Mr. PU Zhongjie's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after the resignation of Mr. PU Zhongjie.
GUO Tongjun	1,466,651.00	365,651.00		1,101,000.00	Restricted circulation stock held by senior executives	During Mr. GUO Tongjun's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Zhibin ZHANG	163,125.00			163,125.00	Restricted circulation stock held by senior executives	During Mr. ZHANG Zhibin's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company

						within half a year after his resignation.
WEI Zhanjiang	145,200.00			145,200.00	Restricted circulation stock held by senior executives	During Mr. WEI Zhanjiang's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
WANG Yong	143,775.00			143,775.00	Restricted circulation stock held by senior executives	During Ms. WANG Yong's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after her resignation.
CHEN Juan	8,700.00			8,700.00	Restricted circulation stock held by senior executives	Within six months after the original term expires, Ms. CHEN Juan will transfer no more than 25% of the total shares of the Company each year.
Feng Xiaoying	5,550.00			5,550.00	Restricted circulation stock held by senior executives	During Ms. FENG Xiaoying's employment in the Company, the annual

						transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after her resignation.
Zheng Guorui	22,500.00			22,500.00	Restricted circulation stock held by senior executives	During Mr. ZHENG Guorei's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Total	268,334,708.00	2,712,346.00	0.00	265,622,362.00		

III. Other Major Events

Applicable Not applicable

In January, 2023, 17,684,396 GDRs issued by the Company approved by China Securities Regulatory Commission (hereinafter referred to as "China Securities Regulatory Commission"), the number of A-share shares corresponding to the surviving number of GDR is less than 50% of the number of A-share basic shares corresponding to the actual GDR issued by the Company approved by China Securities Regulatory Commission. The redemption of GDR will cause the number of A shares of the Company held by the depository of Deutsche Bank Trust Company Americas as the nominal holder to decrease accordingly according to GDR cancellation instruction and enter the domestic market for circulation and trading.

IV. Quarterly Financial Statements

(I) Financial Statements

1. Consolidated Balance Sheet

Prepared by: Lepu Medical Technology (Beijing) Co., Ltd.

Unit: RMB

Item	2023.3.31	2023.1.1
Current assets:		
Cash at bank and on hand	5,297,999,204.12	5,467,278,785.39
Settlement reserve		
Lending funds		
Financial assets held-for-trading	254,840,893.06	277,214,058.48
Derivative financial assets		
Notes receivable	95,380,761.00	98,366,738.81
Accounts receivable	1,828,774,486.43	1,908,630,201.32
Receivable financing	104,315,834.59	134,291,997.64
Prepayments	448,692,190.85	381,572,138.38
Insurance premium receivable		
Reinsurance premium receivable		
Reserves for reinsurance contracts receivable		
Other receivables	160,781,320.26	124,645,400.43
Including: Interests receivable		
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	2,417,036,198.85	2,266,591,888.06
Contract assets		
Assets held for sale		
Non-current assets due within one year	4,257,563.27	4,844,368.53
Other current assets	110,387,096.97	85,517,197.42
Total current assets	10,722,465,549.40	10,748,952,774.46
Non-current assets:		
Loans and advances granted		
Debt investments		
Other debt investments		
Long-term receivables	8,050,790.70	8,259,759.08
Long-term equity investments	1,209,323,392.33	1,229,469,446.74
Investments in other equity instruments	1,213,163,817.81	1,168,919,655.06
Other non-current financial assets	164,770,000.00	158,610,000.00
Investment properties	311,365,691.53	330,246,655.45
Fixed assets	2,615,409,533.41	2,604,619,204.30
Construction in progress	1,601,186,923.62	1,513,606,170.30
Productive biological assets		
Oil and gas assets		
Right-of-use assets	181,691,730.27	221,916,109.85
Intangible assets	1,379,956,948.07	1,369,652,469.86
Development costs	1,045,839,485.58	988,319,738.44
Goodwill	3,330,976,810.89	3,330,976,810.89
Long-term deferred expenses	223,610,580.51	232,882,532.36
Deferred income tax assets	129,493,175.92	131,471,432.98

Other non-current assets	422,598,086.82	446,130,385.24
Total non-current assets	13,837,436,967.46	13,735,080,370.55
Total assets	24,559,902,516.86	24,484,033,145.01
Current liabilities:		
Short-term borrowings	311,678,033.93	380,767,436.73
Loans from central bank		
Placements from banks and other financial institutions		
Financial liabilities held-for-trading	1,500,301.55	
Derivative financial liabilities		
Notes payable	139,177,968.16	182,573,344.20
Accounts payable	1,194,618,684.56	1,337,648,654.76
Advances from customers		
Contract liabilities	320,077,738.00	731,115,959.06
Securities sold under agreements to repurchase		
Deposits from customers and inter banks		
Receiving from vicariously traded securities		
Receiving from vicariously sold securities		
Employee benefits payable	61,787,123.31	206,701,431.48
Taxes payable	256,614,531.71	332,693,089.65
Other payables	427,013,823.09	481,937,974.61
Including: Interests payable		
Dividends payable	3,353,503.56	3,353,503.56
Fee and commission payable		
Reinsurance accounts payable		
Liabilities held-for-sale		
Non-current liabilities due within one year	1,480,873,055.19	1,560,077,144.38
Other current liabilities	77,370,298.57	109,821,099.32
Total current liabilities	4,270,711,558.07	5,323,336,134.19
Non-current liabilities:		
Reserve fund for insurance contracts		
Long-term borrowings	1,167,791,298.83	731,548,392.02
Bonds payable	1,513,534,004.81	1,506,513,884.78
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	133,263,426.93	162,725,224.80
Long-term payables		
Long-term employee benefits payable		
Estimated liabilities		
Deferred incomes	180,441,120.91	183,747,808.29
Deferred income tax liabilities	211,807,574.71	205,678,436.74
Other non-current liabilities		
Total non-current liabilities	3,206,837,426.19	2,790,213,746.63
Total liabilities	7,477,548,984.26	8,113,549,880.82
Shareholders' equity:		
Share capital	1,880,609,906.00	1,880,609,691.00
Other equity instruments	214,752,726.96	214,753,553.08
Including: Preferred shares		
Perpetual bonds		
Capital reserve	3,281,819,976.72	3,243,079,193.31

Less: Treasury shares	355,820,438.37	355,820,438.37
Other comprehensive income	-48,994,885.56	-90,764,197.71
Special reserve		
Surplus reserve	664,046,161.45	664,046,161.45
Provision for general risks		
Retained earnings	10,187,223,021.04	9,590,298,798.54
Total equity attributable to shareholders of the Company	15,823,636,468.24	15,146,202,761.30
Non-controlling interests	1,258,717,064.36	1,224,280,502.89
Total equity	17,082,353,532.60	16,370,483,264.19
Total liabilities and equity	24,559,902,516.86	24,484,033,145.01

Legal representative: Pu Zhongjie Chief Financial Officer: Wang Yong Accounting Manager: Li Yun

2. Consolidated Profit Statement

Unit: RMB

Item	Three Months Ended March 31, 2023	Three Months Ended March 31, 2022
I. Total operating revenue	2,437,202,386.92	2,549,111,243.52
Including: Operating revenue	2,437,202,386.92	2,549,111,243.52
Interest income		
Premium earned		
Income for handling charges and commissions		
II. Total operating costs	1,749,019,988.44	1,840,886,155.20
Including: Operating cost	805,474,394.75	925,270,818.07
Interest expense		
Handling charges and commissions		
Refunded premiums		
Net amount of compensation payout		
Net amount withdrawn for insurance contract reserves		
Policy dividend expense		
Reinsurance expenses		
Taxes and surcharges	24,992,941.86	27,111,746.87
Selling expenses	440,814,329.67	470,555,333.54
Administrative expenses	193,623,961.57	176,301,979.88
Research and development expenses	229,686,257.30	212,393,810.51
Financial expenses	54,428,103.29	29,252,466.33
Including: Interest expenses	43,468,101.66	44,438,791.14
Interest income	34,161,881.52	15,282,743.75
Add: Other income	25,753,889.40	8,674,453.80
Investment income ("-" for loss)	-21,542,984.71	-26,610,840.66
Including: Income from investments in associates and joint ventures	-19,822,646.61	-26,868,030.03
Gains from		

derecognition of financial assets measured at amortised cost		
Exchange gain ("-" for loss)		
Net exposure hedging benefits ("-" for loss)		
Gains from change in fair value ("-" for loss)	5,759,598.45	-4,980,000.00
Loss on impairment of credit ("-" for loss)	-440,479.31	-778,588.80
Loss on impairment of assets ("-" for loss)	877,615.53	-78,012.65
Gains from disposal of asset ("-" for loss)	1,253,000.35	68,193.85
III. Operating profit ("-" for loss)	699,843,038.19	684,520,293.86
Add: Non-operating revenue	33,162,344.03	3,215,233.28
Less: Non-operating expenses	2,046,253.57	8,226,274.40
IV. Total profit before tax (total loss is filled by "-")	730,959,128.65	679,509,252.74
Less: Income tax expens	112,640,660.86	117,380,617.22
V. Net profit ("-" for net loss)	618,318,467.79	562,128,635.52
(I) Classification by continuity of operations		
1. Net profit from continuing operations ("-" for net loss)	618,318,467.79	562,128,635.52
2. Net profit from discontinued operations ("-" for net loss)		
(II) Classification by ownership		
1. Net profit attributable to shareholders of the Company ("-" for net loss)	596,924,222.49	545,393,656.31
2. Net profit attributable to non-controlling interests ("-" for net loss)	21,394,245.30	16,734,979.21
VI. Net other comprehensive income after tax	38,892,944.33	-136,494,905.71
Net other comprehensive income after tax attributable to shareholders of the Company	41,769,312.15	-125,585,331.00
(I) Other comprehensive income that will not be subsequently reclassified to profit or loss	33,688,592.78	-91,873,660.73
1. Change in remeasurement of defined benefit plans		
2. Share of other comprehensive income accounted for using equity method that will not be reclassified to profit or loss		
3. Changes in fair value of investments in other equity instruments	33,688,592.78	-91,873,660.73
4. Changes in fair value of other equity instrument investments		
5. Others		
(II) Other comprehensive incomes that will be subsequently reclassified to profit or loss	8,080,719.37	-33,711,670.27

1. Share of other comprehensive income accounted for using equity method that will be reclassified to profit or loss	31,111.93	
2. Change in fair value of other debt investments		
3. Amount of financial assets reclassified into other comprehensive income		
4. Provision for credit impairment of other debt investments		
5. Cash flow hedging reserve		
6. Exchange differences arising from translation of foreign currency financial statements	8,049,607.44	-33,711,670.27
7. Others		
Net other comprehensive income attributable to non-controlling interests after tax	-2,876,367.82	-10,909,574.71
VII. Total comprehensive income	657,211,412.12	425,633,729.81
(I) Total comprehensive income attributable to shareholders of the the Company	638,693,534.64	419,808,325.31
(II) Total comprehensive income attributable to non-controlling interests	18,517,877.48	5,825,404.50
VIII. Earnings per share:		
(I) Basic earnings per share	0.3205	0.3054
(II) Diluted earnings per share	0.3177	0.3030

As for the business merger under the same control in the current period, net profits achieved by the merged party before the merger is RMB 0.00, and the net profit achieved by the acquiree for the prior period is RMB 0.00.

Legal representative: Pu Zhongjie Chief Financial Officer: Wang Yong Accounting Manager: Li Yun

3. Consolidated Cash Flow Statement

Unit: RMB

Item	Three Months Ended March 31, 2023	Three Months Ended March 31, 2022
I. Cash flows from operating activities:		
Cash received from sale of goods or rendering of services	2,221,855,789.57	2,714,289,424.12
Net increase in deposit from customer and due from bank and other financial institutions		
Net increase in borrowings from central bank		
Net increase in borrowings from other financial institutions		
Cash received from premium income from direct insurance contracts		
Net cash received from reinsurance business		
Net increase in policyholders' deposits and investments contract liabilities		

Cash received from interests, handling charges and commissions		
Net increase in loans from other banks and other financial institutions		
Net increase in repurchase business		
Net cash received from agency purchases and sales of securities		
Cash received from tax refund	46,248,595.98	32,162,102.57
Cash received relating to other operating activities	52,383,241.05	29,461,078.15
Sub-total of cash inflows from operating activities	2,320,487,626.60	2,775,912,604.84
Cash paid for goods and services	898,115,503.14	999,698,743.32
Net increase in loans and advances to customers		
Net increase in central bank and interbank deposits		
Cash paid for claims of direct insurance contracts		
Net increase in lending funds		
Cash paid for interests, handling charges and commissions		
Cash paid for the policy dividends		
Cash paid to and on behalf of employees	715,632,096.89	627,795,527.85
Payments of taxes and surcharges	392,054,371.25	253,956,993.97
Cash paid relating to other operating activities	448,889,090.33	445,528,448.51
Sub-total of cash outflows from operating activities	2,454,691,061.61	2,326,979,713.65
Net cash flows from operating activities	-134,203,435.01	448,932,891.19
II. Cash flow from investing activities:		
Cash received from disposal of investments	279,402,015.38	23,362,144.75
Cash received from investment income	9,775,641.60	4,738,985.75
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	63,808.20	1,128,850.00
Net cash received from the disposal of subsidiaries and other business entities		
Cash received relating to other investing activities	600,000.00	
Sub-total of cash inflows from investing activities	289,841,465.18	29,229,980.50
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets.	210,645,996.42	228,318,131.83
Cash paid for investments	260,817,249.97	102,611,914.00
Net increase in pledge loans		

Net cash paid for acquisition of subsidiaries and other business units		21,126,911.42
Cash paid relating to other investing activities	30,788,197.13	113,903,761.64
Sub-total of cash outflows from investing activities	502,251,443.52	465,960,718.89
Net cash flows from investing activities	-212,409,978.34	-436,730,738.39
III. Cash flow from financing activities:		
Cash received from capital contributions	431,940.00	
Including: Cash received by subsidiaries from receiving investments made by minority interest	431,940.00	
Cash received from borrowings	617,000,000.00	834,000,000.00
Cash received relating to other financing activities	38,987,595.51	26,109,784.73
Sub-total of cash inflows from financing activities	656,419,535.51	860,109,784.73
Cash repayment of borrowings	327,500,000.00	803,510,360.00
Cash payments for distribution of dividends profits or interest expenses	23,452,766.31	27,329,689.17
Including: Dividends and profits paid by subsidiaries to non-controlling interests		
Cash payments for other financing activities	54,988,625.07	194,643,420.84
Sub-total of cash outflows from financing activities	405,941,391.38	1,025,483,470.01
Net cash flows from financing activities	250,478,144.13	-165,373,685.28
IV. Effect of change in foreign exchange rate on cash and cash equivalents	-42,618,023.43	-1,032,594.72
V. Net Increase in cash and cash equivalents	-138,753,292.65	-154,204,127.20
Add: Beginning balance of cash and cash equivalents	5,309,297,789.78	3,684,043,645.03
VI. Ending balance of cash and cash equivalents	5,170,544,497.13	3,529,839,517.83

(II) Audit Report

Whether the First Quarter Report has been audited

Yes No

The Company's First Quarter Report has not been audited.

Lepu Medical Technology (Beijing) Co., Ltd.

Board of Directors